Streetbeat News

Partnerships

LZM

Lifezone Metals Limited (NYSE:LZM) reported a reduced loss per share of $0.14 for H1 2024, down from $0.18 in H1 2023. The company is progressing its Kabanga Nickel Project in Tanzania, with the Definitive Feasibility Study expected to be completed by the end of September. Lifezone is also advancing a partnership with Glencore to recycle platinum, palladium, and rhodium in the U.S. The company maintains a healthy cash position of $63.5 million as of June 30, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:10 pm

ALZN

Alzamend Neuro shares are trading higher following the announcement of a partnership with Massachusetts General Hospital to conduct a Phase II clinical study of AL001 for PTSD treatment.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:08 pm

ABL

Abacus Life, Inc. (NASDAQ: ABL) and Lorisco Life LLC have announced the launch of PREADISAN™, a health prediction platform that uses machine learning and proteomics to improve health predictions. This partnership aims to enhance Abacus' longevity and actuarial technology services by providing more personalized risk scores.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:06 pm

FOUR

The Indianapolis Colts have partnered with Shift4 to implement end-to-end payment solutions for ticketing transactions at Lucas Oil Stadium starting in the 2024 season.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:06 pm

ALZN

Alzamend Neuro has partnered with Massachusetts General Hospital for a Phase II study of AL001 for PTSD treatment. The study will be led by Harvard Associate Professor Dr. Ovidiu Andronesi and will compare AL001 to marketed lithium carbonate in the human brain.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:04 pm

CCG

Cheche Group has expanded its partnership with ARCFOX and launched a full-service insurance platform. The company also plans to offer ancillary products such as GAP and extended warranty insurance.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:03 pm

ACN

Accenture (NYSE:ACN) has invested in Earli Inc., a biotech company specializing in early cancer detection. This strategic investment aims to expand collaborations with global health and pharma companies, enhancing cancer detection and treatment capabilities.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 12:00 pm

SPRC

SciSparc Ltd. (NASDAQ: SPRC) has signed an exclusive patent license agreement with Polyrizon Ltd to out-license its SCI-160 program for pain treatment. SciSparc will receive Polyrizon securities valued at $3 million and potentially milestone fees and royalties. SCI-160 has shown promising preclinical results. Additionally, SciSparc has agreed to a merger with AutoMax Motors Ltd. SPRC stock is up 21.8% in premarket trading.

Portfolio Pulse from Vandana Singh

August 19, 2024 | 11:51 am

GOOGL

META

NVDA

SPY

TSM

VOO

Nvidia Corp (NASDAQ:NVDA) has seen significant changes in hedge fund ownership, with Citadel and DE Shaw reducing their stakes, while Renaissance Technologies and Marshall Wace increased their investments. Nvidia's stock has gained close to 3% in the last 30 days. SoftBank Group Corp has shifted to Taiwan Semiconductor Manufacturing Co (NYSE:TSM) for AI chip production, and is exploring partnerships with Alphabet Inc (NASDAQ:GOOGL) (NASDAQ:GOOG) and Meta Platforms Inc (NASDAQ:META). Investors can gain exposure to Nvidia through Vanguard S&P 500 ETF (NYSE:VOO) and SPDR S&P 500 (NYSE:SPY).

Portfolio Pulse from Anusuya Lahiri

August 19, 2024 | 11:48 am

MIRA

MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) is nearing the submission of its Investigational New Drug (IND) application for Ketamir-2 by the end of the year. The company has strengthened its leadership with the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Significant progress has been made with Ketamir-2, a novel oral ketamine analog, which has shown a superior safety profile and efficacy in preclinical studies. Additionally, MIRA-55, a novel oral pharmaceutical marijuana analog, has demonstrated promising results and is not classified as a controlled substance by the DEA.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 11:35 am